SEQSTER Unlocks Data from 150M Patients to Reshape Clinical Trials

SAN DIEGO, CA – March 05, 2026 – Healthcare technology firm SEQSTER has launched its 1-Click DataLake™, a new platform poised to significantly alter the landscape of clinical research by providing life sciences companies with real-time access to de-identified data from over 150 million patients nationwide.

Built on a foundation of more than a decade of aggregated electronic health record (EHR) data, the platform aims to accelerate every phase of the research lifecycle, from initial study design and patient recruitment to the generation of real-world evidence (RWE). The company, which debuted the platform at the Precision Medicine World Conference 2026, asserts that this technology will provide a critical infrastructure layer for the future of medicine.

“We are turning health data into medicine for our clients,” said Ardy Arianpour, CEO & Co-Founder of SEQSTER, in a statement accompanying the launch. “With longitudinal, research-ready data from 150M+ patients, we’re now providing a turnkey real world data infrastructure that accelerates study design, optimizes patient recruitment, and enables evidence generation.”

Supercharging Research with AI-Ready Data

The central challenge in leveraging real-world data has long been the fragmented and inconsistent nature of patient information. Data is often siloed across different hospitals, clinics, and labs, recorded in disparate formats, and notoriously “messy.” This makes creating a cohesive, longitudinal view of a patient’s health journey—a record that tracks their health over time—a monumental task.

SEQSTER's platform is engineered to tackle this problem head-on. It functions as a patient-centric “operating system” that connects, collects, and refines this fragmented data into a unified stream. A key component of this process is the recently unveiled 1-Click Data Refinery™, an engine designed to transform raw EHR data into clean, structured, and AI-ready formats. By harmonizing data at the source, the platform addresses the “garbage in, garbage out” problem that plagues many artificial intelligence initiatives, producing high-quality data that can be used for rapid model training and real-time analysis.

This technological backbone allows researchers to move beyond slow, manual chart reviews. Instead, they can query the vast dataset in real-time to identify patterns, test hypotheses, and screen potential trial participants with unprecedented speed. The platform’s adherence to modern interoperability standards, such as FHIR (Fast Healthcare Interoperability Resources), ensures that this harmonized data can be seamlessly integrated into existing research workflows, making it accessible and actionable at scale.

A New Tool for Health Equity and Inclusion

The launch arrives at a pivotal moment for clinical research, as regulatory bodies push for greater diversity in clinical trials. The Food and Drug Omnibus Reform Act (FDORA) of 2022 now mandates that sponsors of late-stage clinical trials submit a Diversity Action Plan (DAP). This legislation reflects a growing consensus that trials must accurately represent the patient populations they are intended to serve to ensure that new treatments are safe and effective for everyone.

SEQSTER's platform is explicitly designed to support this mandate. The company states its DataLake includes “deep integration with diverse and historically underserved populations,” providing researchers with the tools to identify and recruit participants from a wide range of demographic and geographic backgrounds. By empowering patients to consent and share their verified clinical records regardless of their location or health system, the technology helps break down historical barriers that have excluded certain communities from research.

This capability is critical for sponsors looking to design more equitable studies and meet the FDA's stringent new requirements. Access to a diverse, queryable dataset allows for the precise identification of patient cohorts that match specific demographic and clinical criteria, streamlining the development of effective recruitment strategies and helping to ensure that the resulting evidence is generalizable to a broader population.

Navigating a Crowded Field of Data Titans

SEQSTER enters a competitive real-world data market populated by established giants and specialized firms. Companies like IQVIA boast enormous global datasets, while others like Flatiron Health and Verana Health have carved out niches in specific therapeutic areas such as oncology and ophthalmology. TriNetX has also become a major player by offering a global network for real-time cohort identification.

Against this backdrop, SEQSTER aims to differentiate itself through its patient-centric, consent-driven model and its advanced data refinement capabilities. While many platforms aggregate data, SEQSTER’s emphasis on transforming raw, messy data into an AI-ready asset positions it as a key enabler for the next generation of data-driven research. The platform’s architecture, which prioritizes creating a clean, longitudinal patient record, is designed to fuel sophisticated analytics and machine learning applications that require high-fidelity data.

Furthermore, the platform's commitment to robust privacy and security protocols is fundamental to its operation. By using de-identification and tokenization methods that align with regulations like HIPAA, it allows for longitudinal tracking of patient data while protecting individual privacy, building the trust necessary for both patients and research organizations to participate.

Early Adoption Signals Industry-Wide Impact

Beyond the launch announcement, early signs of market adoption suggest that SEQSTER’s approach is gaining traction. The company’s partners already include a formidable list of pharmaceutical leaders, healthcare providers, and government agencies, including Takeda, Novartis, United Healthcare, and the Centers for Medicare and Medicaid Services (CMS).

Testimonials from these partners underscore the platform's practical value. An executive at a leading clinical research organization highlighted how integrating the technology significantly expedited the acquisition of medical records, a critical step for determining trial eligibility. Similarly, a technology leader at a major pharmaceutical partner praised the system for providing enhanced access to real-world evidence and integrating real-time data directly into research workflows.

By enabling researchers to rapidly access and analyze high-quality, longitudinal data from millions of patients, the 1-Click DataLake™ has the potential to dramatically shorten drug development timelines, reduce costs, and lead to the creation of more effective and equitable medicines. As the life sciences industry continues its shift toward data-driven decision-making, the ability to turn vast stores of real-world information into actionable intelligence will be more critical than ever.